New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
10:00 EDTBNPQY, USB, TRMB, NGLS, SBS, OHI, MM, DLAKY, HRL, HOG, EPB, CJES, BMY, BZH, VEOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BNP Paribas (BNPQY) downgraded to Neutral from Overweight at HSBC... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... Bristol-Myers (BMY) downgraded to Equal Weight from Overweight at Barclays... C&J Energy (CJES) downgraded to Equal Weight at Stephens... El Paso Pipeline (EPB) downgraded to Sell from Neutral at Goldman... Harley-Davidson (HOG) downgraded to Market Perform from Strong Buy at Raymond James... Hormel Foods (HRL) downgraded at Credit Suisse... Lufthansa (DLAKY) downgraded to Equal Weight from Overweight at Barclays... Millennial Media (MM) downgraded at Evercore... Omega Healthcare (OHI) downgraded to Neutral from Buy at Goldman... Saneamento Basico (SBS) downgraded to Sector Perform from Outperform at Scotia... Targa Resources Partners (NGLS) downgraded to Equal Weight at Barclays... Trimble (TRMB) downgraded to Neutral from Buy at Janney Capital... U.S. Bancorp (USB) downgraded at RW Baird... Veolia Environment (VE) downgraded to Equal Weight from Overweight at Morgan Stanley.
News For BNPQY;BZH;BMY;CJES;EPB;HOG;HRL;DLAKY;MM;OHI;SBS;NGLS;TRMB;USB;VE From The Last 14 Days
Check below for free stories on BNPQY;BZH;BMY;CJES;EPB;HOG;HRL;DLAKY;MM;OHI;SBS;NGLS;TRMB;USB;VE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 16, 2014
09:54 EDTUSBU.S. Bancorp says loan demand "strong" across the U.S.
09:44 EDTUSBU.S. Bancorp sees efficiency ratio in the low 50s going forward
Sees net charge offs, nonperforming assets remaining "relatively stable" in Q3. Says capital position is "strong." Comments made on the Q2 earnings conference call.
07:22 EDTUSBU.S. Bancorp reports end Q2 book value per share $20.98
Subscribe for More Information
07:19 EDTUSBU.S. Bancorp reports Q2 common equity tier 1 capital ratio 9.6%
Subscribe for More Information
07:17 EDTUSBU.S. Bancorp reports Q2 EPS 78c, consensus 77c
Subscribe for More Information
06:26 EDTBMYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
17:29 EDTNGLSTarga Resources Partners increases quarterly dividend by 2% to 78c
Subscribe for More Information
16:33 EDTOHIOmega Healthcare increases quarterly dividend to 51c from 50c
Subscribe for More Information
15:19 EDTUSBNotable companies reporting before tomorrow's open
Subscribe for More Information
11:13 EDTBMYPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTEPBOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Adecogro (AGRO) downgraded to Underperform from Neutral at BofA/Merrill... Campbell Soup (CPB) downgraded to Sell from Neutral at Goldman... Credicorp (BAP) downgraded to Neutral from Overweight at JPMorgan... El Paso Pipeline (EPB) downgraded to Neutral from Buy at Citigroup... Kellogg (K) downgraded to Sell from Neutral at Goldman... Kodiak Oil & Gas (KOG) downgraded to Market Perform from Outperform at BMO Capital... Lexmark (LXK) downgraded at Bernstein... Maxim Integrated (MXIM) downgraded to Equal Weight from Overweight at Barclays... Republic Airways (RJET) downgraded to Underperform from Neutral at BofA/Merrill... Sasol (SSL) downgraded to Neutral from Buy at Citigroup... Time Warner (TWX) downgraded to Equal Weight from Overweight at Evercore.
07:35 EDTBMYPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
06:36 EDTDLAKYLufthansa poised to reduce Venezuela flights amid forex battle, Reuters says
Subscribe for More Information
05:32 EDTEPBEl Paso Pipeline downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
July 14, 2014
10:00 EDTSBSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:23 EDTSBSSABESP downgraded to Sell from Neutral at Citigroup
Subscribe for More Information
06:38 EDTTRMBTrimble acquires The Omega Group, terms not disclosed
Subscribe for More Information
July 11, 2014
07:20 EDTUSBBig banks seen losing reserve release cushion, Reuters says
Releasing loan-loss reserves has helped U.S. big banks weather a period of weak loan demand and lower fee income, but Q2 results from the banks may see less benefit from the practice as loss rates and reserves near their lower limits, said Reuters. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
July 10, 2014
12:43 EDTBMYBristol-Myers announces plans for Q3 submission of Opdivo BLA
Bristol-Myers Squibb announced earlier that, following discussions with the FDA, the company is planning a Q3 submission of a Biologics Licensing Application for Opdivo for previously treated advanced melanoma. This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.S. “We continue to collaborate closely with the FDA on Opdivo and the planned submission in advanced melanoma represents an important step forward in our company’s commitment to deliver innovative treatment options for patients with cancer,” said Michael Giordano, MD, Head of Oncology Development, Bristol-Myers Squibb. The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine or carboplatin/paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy and, if BRAF-mutation positive, a BRAF inhibitor regimen. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trade name for nivolumab.
06:24 EDTBNPQYBNP enters guilty plea in U.S. to overstepping sanctions, Reuters says
BNP Paribas entered a guilty in Manhattan federal court to overstepping U.S. sanctions after agreeing to pay $8.97B to resolve state and federal investigations that reached the highest echelons of French and American diplomacy, according to Reuters, citing comments from Assistant U.S. Attorney Andrew Goldstein. The bank's sentencing date is set for October 3. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use